B-cell Non-hodgkin Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis
DelveInsight's, 'B-Cell Non-Hodgkin Lymphoma - Pipeline Insight, 2025' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in B-Cell Non-Hodgkin Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 75 major companies are actively engaged in the development of more than 80 treatment therapies for B-cell non-Hodgkin lymphoma.
B-cell Non-hodgkin Lymphoma Overview:
B-cell non-Hodgkin lymphoma (NHL) is a type of cancer that arises from abnormal B lymphocytes—white blood cells essential to the immune system. It accounts for over 85% of all NHL cases, making it the most common subtype. B-cell NHL includes several subtypes, classified based on cell morphology, surface proteins, and genetic traits. Key subtypes include diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and Burkitt lymphoma. The disease typically starts in the lymph nodes or lymphoid tissues and can spread to other organs, such as the gastrointestinal tract. Common symptoms include painless swollen lymph nodes, fever, night sweats, fatigue, weight loss, itchy skin, and pain in the chest, abdomen, or bones. When fever, night sweats, and weight loss occur together, they are known as B symptoms and are important for staging and prognosis.
Diagnosing B-cell NHL—especially types with small- to medium-sized cells—can be difficult due to their resemblance to reactive lymphadenopathy and other lymphomas. Accurate diagnosis relies on a combination of techniques, including immunohistochemistry and flow cytometry, which must be interpreted in the context of the patient's clinical presentation and cellular morphology. Proper recognition of cytologic features is key to choosing the right diagnostic tests. Subtypes such as marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, CLL/SLL, and lymphoplasmacytic lymphoma are often misdiagnosed based on cytology alone. Therefore, a lymph node biopsy is usually necessary for definitive diagnosis and proper classification.
"B-cell Non-hodgkin Lymphoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-cell Non-hodgkin Lymphoma Therapeutics Market.
Key Takeaways from the B-cell Non-hodgkin Lymphoma Pipeline Report
DelveInsight's B-cell Non-hodgkin Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for B-cell Non-hodgkin Lymphoma treatment.
In May 2023, Bristol Myers Squibb announced positive topline results from two studies: TRANSCEND FL, a global, multicenter Phase 2 study evaluating Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1 study assessing Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met the primary endpoint of overall response rate, with Breyanzi showing statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.
In May 2023, Janssen Biotech, a subsidiary of Johnson & Johnson, announced a global collaboration and licensing agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation CAR T-cell therapies for treating B-cell malignancies.
In May 2023, Genmab A/S revealed that the FDA approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, after two or more lines of systemic therapy.
In January 2023, Fate Therapeutics, Inc. announced it had declined a proposal from Janssen Biotech to continue their collaboration and option agreement under revised terms, leading to the termination of the agreement and the winding down of all collaboration activities in the first quarter of 2023.
Key B-cell Non-hodgkin Lymphoma companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy, Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics, and others are evaluating new drugs for B-cell Non-hodgkin Lymphoma to improve the treatment landscape.
Promising B-cell Non-hodgkin Lymphoma pipeline therapies in various stages of development include Valemetostat, MB-106, CB-010, LP-284, and others.
B-cell Non-hodgkin Lymphoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the B-cell Non-hodgkin Lymphoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Non-hodgkin Lymphoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the B-cell Non-hodgkin Lymphoma market.
Download our free sample page report on B-cell Non-hodgkin Lymphoma pipeline insights
B-cell Non-hodgkin Lymphoma Emerging Drugs
Valemetostat: Daiichi Sankyo
MB-106: Mustang Bio
CB-010: Caribou Biosciences
LP-284: Lantern Pharma
B-cell Non-hodgkin Lymphoma Companies
Over 75 key companies are working on developing therapies for B-cell non-Hodgkin lymphoma. Among them, Daiichi Sankyo has drug candidates for B-cell non-Hodgkin lymphoma in the advanced Phase II stage.
DelveInsight's report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
B-cell Non-hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
B-cell Non-hodgkin Lymphoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging B-cell Non-hodgkin Lymphoma Therapies and Key Companies: B-cell Non-hodgkin Lymphoma Clinical Trials and advancements
B-cell Non-hodgkin Lymphoma Pipeline Therapeutic Assessment
• B-cell Non-hodgkin Lymphoma Assessment by Product Type
• B-cell Non-hodgkin Lymphoma By Stage
• B-cell Non-hodgkin Lymphoma Assessment by Route of Administration
• B-cell Non-hodgkin Lymphoma Assessment by Molecule Type
Download B-cell Non-hodgkin Lymphoma Sample report to know in detail about the B-cell Non-hodgkin Lymphoma treatment market @ B-cell Non-hodgkin Lymphoma Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. B-cell Non-hodgkin Lymphoma Current Treatment Patterns
4. B-cell Non-hodgkin Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. B-cell Non-hodgkin Lymphoma Late-Stage Products (Phase-III)
7. B-cell Non-hodgkin Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. B-cell Non-hodgkin Lymphoma Discontinued Products
13. B-cell Non-hodgkin Lymphoma Product Profiles
14. B-cell Non-hodgkin Lymphoma Key Companies
15. B-cell Non-hodgkin Lymphoma Key Products
16. Dormant and Discontinued Products
17. B-cell Non-hodgkin Lymphoma Unmet Needs
18. B-cell Non-hodgkin Lymphoma Future Perspectives
19. B-cell Non-hodgkin Lymphoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the B-cell Non-hodgkin Lymphoma Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
28 minutes ago
- Globe and Mail
UNH or ELV: Which Healthcare Titan Will Regain Investor Trust First?
UnitedHealth Group Incorporated UNH and Elevance Health, Inc. ELV are two of the largest health insurers in the United States, each operating vast networks and diversified healthcare businesses. Today, both face intense headwinds: medical costs are running hotter than expected, regulatory burdens are mounting, and investors have grown uneasy after a string of disappointments. This year, each stock has seen significant declines, reflecting sector-wide uncertainty. Shares of UnitedHealth have plunged 40.7% in the year-to-date period, while Elevance declined 16%. The broader industry has slumped 31.6% during this time, while the S&P 500 Index witnessed 8.8% growth, backed by tech-related stocks. While both insurers have endured recent pressure, their operational strategies and financial resilience differ in critical ways. Let's dive deep and closely compare the fundamentals of the two stocks to determine which company is better positioned to restore investor confidence. The Case for UnitedHealth UnitedHealth remains the industry's heavyweight, with a market cap of $275.5 billion, nearly four times Elevance's $70.3 billion. Its debt profile is stronger too, with a debt-to-EBITDA ratio of 2.03 compared to ELV's 2.47. UNH delivers insurance coverage through UnitedHealthcare and health services via Optum, integrating provider, pharmacy-benefit and analytics services. This vertical integration gives UNH strong insight and influence over cost drivers and care utilization. Its operational scale and bargaining power help it negotiate more favorable provider and pharmaceutical contracts compared to smaller players. In recent quarters, despite cost pressures, UNH has consistently generated robust cash flow, giving it the flexibility to keep investing in growth and weather downturns. That said, cracks are showing: the company lowered its outlook (even pulled it for a brief period) after missing estimates for the first two quarters of 2025. Medicare Advantage and Medicaid segments have seen margin pressure from unexpected utilization spikes, injecting near-term uncertainty. However, UNH's diversified business lines and ability to pivot through Optum's services provide it with multiple levers to respond to such volatility. The recent Amedisys acquisition extends its reach into in-home care, a move expected to curb medical costs by reducing hospitalizations. Adding to its credibility, Warren Buffett's Berkshire Hathaway recently disclosed a $1.57 billion stake of more than 5 million in UNH, as of June 30, 2025. Buffett's seal of approval often sparks a wave of copycat buying, reinforcing market confidence in the long-term story. The Case for Elevance Elevance also benefits from structural tailwinds like an aging population and expanding into government programs. Its Carelon platform is driving digital and AI-enabled solutions to personalize care, cut costs and sharpen margins, pillars of its future competitiveness. During the first half of 2025, Elevance managed to generate 15.5% growth in premiums, outpacing UNH's 12.6%. Growing memberships in ELV's Dental, Vision, Medicare Advantage and individual commercial plans should sustain this momentum. ELV is also contending with elevated medical cost trends, particularly in the ACA and Medicaid segments. This has led to an earnings miss in the second quarter of 2025, with the benefit expense ratio increasing to 88.9% from the 2024-end level of 88.5%, suggesting that a large chunk of premium revenue is going toward claims rather than profitability. For the full year, the metric is expected to hit 90%. Elevance Health, Inc. Price, Consensus and EPS Surprise Elevance Health, Inc. price-consensus-eps-surprise-chart | Elevance Health, Inc. Quote By contrast, UNH's medical care ratio increased to 89.4% in the second quarter from 85.5% in 2024. We expect the metric to average at 89.4% in 2025, signalling relatively strongerprofitability. Elevance's return on capital of 10.4% is below the industry average of 12.2% and UNH's 13%. Both companies have taken shareholder-value boosting moves. In the first half of 2025, ELV returned more than $2 billion to shareholders through repurchases and dividends, while UNH returned $9.5 billion. ELV's dividend yield of 2.21% is lower than that of UNH's 2.95%. Nevertheless, Elevance's Carelon segment, which integrates physical, behavioral and social care, is growing rapidly, providing diversification benefits. Recent buyouts in home health and pharmacy services, higher CarelonRx product revenues and the scaling of innovative risk-based capabilities in Carelon Services are major positives. How Do Zacks Estimates Compare for UNH & ELV? Both companies are contending with unfavorable estimates from analysts for 2025 earnings due to the rising costs trend. The Zacks Consensus Estimate for UNH's 2025 and 2026 EPS is pegged at $16.58 and $18.08, indicating a year-over-year decline of 40.1% and growth of 9%, respectively. Image Source: Zacks Investment Research Meanwhile, the same for ELV is pegged at $30.15 and $32.19 for 2025 and 2026, signaling an 8.8% decline and 6.8% growth, respectively. All these estimates remained stable over the past week. Valuation: UNH vs. ELV Coming to the valuation story, it seems that investors are willing to pay a premium for UnitedHealth compared to Elevance. This is reflected in UNH's forward 12-month price/earnings (P/E) of 17.23X compared with ELV's 9.72X. Both are currently trading below their five-year median P/E value. Bottom Line UnitedHealth and Elevance both face steep challenges as rising medical costs, regulatory hurdles and shaken investor sentiment weigh on the entire sector. Yet, UnitedHealth has the edge thanks to its unmatched scale, diversified Optum platform, and stronger balance sheet, which provide multiple levers to manage cost pressures and sustain growth. The Amedisys acquisition further deepens its integrated care model, and Buffett's sizable stake underscores confidence in its long-term resilience. Elevance, while benefiting from Carelon's digital push and strong premium growth, still lags in profitability, debt metrics, capital efficiency and shareholder payouts. Ultimately, even though both stocks currently carry a Zacks Rank #5 (Strong Sell), UnitedHealth appears better positioned to restore confidence as the headwinds ease. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report Elevance Health, Inc. (ELV): Free Stock Analysis Report
Globe and Mail
2 hours ago
- Globe and Mail
Trump administration cuts California sexual-health program grant over transgender policies
The Trump administration on Thursday terminated a grant for a program in California intended to prevent teenage pregnancy and childhood sexually transmitted infections, saying the state refused to remove 'radical gender ideology' from its curriculum. The Personal Responsibility Education Program educates young people on abstinence and contraception to prevent pregnancy and sexually transmitted infections, with particular focus on children who are homeless or living in foster care or in areas with high teen birth rates. The grant was worth US$12-million, said Andrew Gradison, an acting assistant secretary at the U.S. Department of Health and Human Services. 'If you continue to push radical ideology on our children, we will not pay for it anymore,' he told Fox & Friends, saying the program included 'radical gender ideology' without providing details. Canadians with an X gender marker will now have to select male or female on Nexus travel cards after Trump order Gradison said that his department is near completing a review of every state's curriculum, adding that by early next week, nearly 40 states will be notified that they need to change their curriculum or face the same consequences. It is the latest salvo in the Trump administration's fight against transgender rights as well as the state of California, led by Democratic Governor Gavin Newsom. Representatives for Newsom's office could not be immediately reached. Before the announcement, President Donald Trump said any California school district that does not adhere to his administration's transgender policies will not receive federal funding, but gave no other details. Representatives for the White House did not immediately respond to requests for detail following Trump's comment, posted to his social media platform. U.S. schools receive the vast majority of their funding through local and state sources, but do receive some money from the federal government. Trump's administration sued California in July over its policy allowing transgender athletes to compete in girls' school sports, alleging that it was a violation of federal anti-discrimination laws. In February, the Republican president signed a directive to strip federal funding from any school that allows transgender women or girls to compete in female sports.
Globe and Mail
3 hours ago
- Globe and Mail
Nutriband (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity
FDA grants Type C Meeting for AVERSA(TM) Fentanyl to discuss Chemistry, Manufacturing, and Controls pathway from IND submission through NDA approval and commercialization CEO Gareth Sheridan temporarily steps aside to pursue Irish Presidential nomination while Chairman Serguei Melnik assumes interim CEO role during critical development phase Strategic partnership with Kindeva combines proven FDA-approved fentanyl patch technology with Nutriband's proprietary abuse-deterrent platform targeting $80-200 million peak U.S. market opportunity The pharmaceutical development landscape presents a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. The most significant patient impact now comes from innovations that enhance safety profiles of existing therapeutic options, particularly in pain management where the balance between therapeutic benefit and abuse potential creates urgent medical need alongside substantial regulatory complexity. The opioid crisis has reshaped how regulators approach pain management solutions. The most promising opportunities exist at the intersection of proven therapeutic benefit and enhanced safety mechanisms, requiring both technological innovation and regulatory expertise to navigate complex approval… Read More>> About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire San Francisco, CA 415.949.5050 Office Editor@ BioMedWire is powered by IBN
